Four Peptides, Four Entirely Different Kinds of Drug

The short version

Peptide Broker brokers information, not product. It is a reading desk for anyone who keeps meeting the word peptide and cannot tell whether any two of them have anything in common.

Mostly they do not. A peptide is just a short chain of amino acids — the same building blocks proteins are made of, only fewer of them. That fact says almost nothing about what a given peptide does. What decides that is its class: which receptor the molecule talks to, and what that receptor happens to control.

The four peptides briefed here sit in four different classes. One nudges the pituitary into releasing a pulse of growth hormone. One imitates two gut hormones that report a meal has arrived. One switches on a brain receptor tied to sexual desire. One is a fragment of collagen that tells skin cells to rebuild. Filing all four under peptides is about as informative as filing a diuretic and an antidepressant under pills.

Everything below is drawn from published studies, each numbered in brackets and listed in full on the references page.

Four classes, not four brands

The organising idea of this desk is that class is the unit of understanding, and compound is only the unit of naming. Once the class is known, most of the rest follows: what the molecule is studied for, where its side effects will show up, and what kind of evidence exists to support it.

Growth hormone secretagogues do not supply a hormone. They provoke one. Ipamorelin binds the growth hormone secretagogue receptor (GHS-R1a) on pituitary somatotrophs — the same receptor the hunger hormone ghrelin uses — and triggers a discrete pulse of growth hormone. In the human pharmacokinetic study, that pulse peaked around forty minutes after dosing and the peptide itself cleared with a terminal half-life of roughly two hours ^[4]. Everything downstream, good and bad, is the body's own growth hormone axis doing what it does.

Incretin mimetics take the opposite approach: they impersonate. Tirzepatide is built on the native sequence of glucose-dependent insulinotropic polypeptide and engineered to activate both the GIP and the GLP-1 receptor, the two gut-hormone receptors that report a meal has arrived. Engaging both enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and reduces food intake.

Melanocortin receptor agonists are neither supplier nor provocateur but switch. PT-141 activates MC4R and MC3R concentrated in the hypothalamus and limbic system, engaging dopaminergic circuitry that governs sexual motivation. In a crossover functional-MRI study of thirty-one premenopausal women with hypoactive sexual desire disorder, melanocortin-4 agonism increased sexual desire for up to twenty-four hours and altered how the brain processed erotic stimuli ^[12].

Copper-binding matrix tripeptides barely belong in the same conversation. GHK-Cu is not a synthetic drug candidate at all but an endogenous fragment: the sequence glycyl-histidyl-lysine occurs inside the alpha-2(I) chain of type I collagen, and plasma levels fall from roughly 200 ng/mL at age twenty to about 80 ng/mL by sixty ^[9]. Bound to copper, it acts locally on fibroblasts and keratinocytes rather than on a hormone axis.

What the phrase ‘research peptide’ actually covers

The phrase is doing a great deal of work, and it hides four completely different regulatory situations.

Tirzepatide is an approved prescription medicine. The StatPearls monograph records its approval as a dual GLP-1 and GIP receptor agonist for type 2 diabetes mellitus in May 2022, alongside its mechanism, indications and safety profile ^[19]; the regulatory record adds later approvals covering chronic weight management and moderate-to-severe obstructive sleep apnoea in adults with obesity.

Bremelanotide — the compound sold informally as PT-141 — is also an approved prescription medicine, but only for acquired, generalised hypoactive sexual desire disorder in premenopausal women, with a labelled 1.75 mg subcutaneous as-needed dose capped at one dose per twenty-four hours and no more than eight doses per month ^[15]. Material sold as ‘PT-141 research chemical’ sits entirely outside that approval.

GHK-Cu occupies a third position: topical Copper Tripeptide-1 is a legal cosmetic ingredient in the United States, the European Union and the United Kingdom, while injectable or oral formulations are unapproved research chemicals with no established regulatory pathway.

Ipamorelin occupies the fourth. It has never been approved as a drug in any jurisdiction. In 2024 the regulator removed ipamorelin acetate from Category 2 of the interim Section 503A bulk drug substances list after the nominator withdrew, and the Pharmacy Compounding Advisory Committee reviewed the substance later that year; it is not an approved bulk substance for compounding. It is additionally prohibited in sport at all times under the anti-doping category covering peptide hormones, growth factors and mimetics, and is detectable in urine by accredited laboratories.

One word, four legal realities. This desk states each compound's standing on its own page rather than letting the category label imply a shared one.

How class predicts the shape of the evidence

Class does not only predict pharmacology. It predicts what kind of study exists to read, which is why a briefing organised this way saves a reader from comparing incomparable things.

The incretin class has been developed inside the pharmaceutical system from the start, so its evidence is large, randomised and comparative: a 72-week trial in 2,539 adults with obesity ^[21], a 40-week trial in 1,879 adults with type 2 diabetes ^[22], and an open-label head-to-head against another approved peptide in 751 adults ^[18]. Questions about this class are settled with confidence intervals.

The melanocortin class has run the same gauntlet but around a subjective endpoint. Two identical Phase 3 trials enrolling 1,267 premenopausal women measured desire and desire-related distress on questionnaire scales ^[13], with a 52-week open-label extension of 684 women following safety over time ^[14]. The numbers are real; whether the size of the change matters to a person is the live argument.

The secretagogue class stalled. The only published Phase 2 randomised trial of ipamorelin — 114 adults after bowel resection — missed its primary endpoint outright ^[3], and the most recent published in-vivo work is a ferret study of chemotherapy-induced weight loss ^[1]. The clinic marketing for this class is far ahead of its trial record, and the gap is the single most important thing to know about it.

The matrix-tripeptide class inverts the pattern completely. Its mechanistic literature is enormous — gene-expression analysis reports GHK modulating about 31.2% of human genes at a fifty-percent-or-greater change threshold ^[7] — while its clinical literature is a handful of small topical studies. Depth of mechanism and depth of outcome evidence are different axes, and GHK-Cu is the clearest demonstration of that in the set.